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Materials
Peptide grade dimethylformamide (DMF) was obtained from Labscan. Amino acids, coupling reagents and resins for Fmoc-solid-phase peptide synthesis (SPPS) were obtained from either Novabiochem or GL Biochem. SPPS was performed in polypropylene syringes equipped with Teflon filters, purchased from Torviq. Analytical reversed-phase high-performance liquid chromatography (HPLC) was performed on either a Waters Acquity UPLC system equipped with PDA eλ detector (λ = 210 -400 nm), Sample Manager FAN and Quaternary Solvent Manager (H-class) modules or a Waters System 2695 separations module with a 2996 photodiode array detector. Peptides were analyzed using an XBridge BEH 5 µm, 2.1 x 150 mm wide-pore column (C-18) at a flow rate of 0.2 mL min -1 on the HPLC system or Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 on the UPLC system. Both instruments were run using a mobile phase composed of 0.1% trifluoroacetic acid in H 2 O (Solvent A) and 0.1% trifluoroacetic acid in acetonitrile (Solvent B) in a linear gradient as indicated. The analysis of the chromatograms was conducted using Empower 3 Pro software (2010) and retention times (R t min) of pure peptides and proteins are reported with the gradients specified.
Preparative and semi-preparative reversed-phase HPLC was performed using a Waters 600E Multisolvent Delivery System with a Rheodyne 7725i Injection valve (4 mL loading loop) and Waters 500 pump with a Waters 490E programmable wavelength detector operating at 214, 230, 254 or 280 nm. Preparative reversed-phase HPLC was performed using a Waters Sunfire C18 column (5 μm, 10 × 250 mm) at a flow rate of 7 mL min −1 . Semi-preparative reversed-phase HPLC was performed using a Waters XBridge-BEH300 wide-pore C18 column (5 μm, 10 x 250 mm) at a flow rate of 4 mL min −1 . Peptides and proteins bearing free sTyr residues were purified using a mobile phase of 0.1 M NH 4 OAc (Solvent A) and acetonitrile (Solvent B) for A Aa or a mobile phase of 0.1% Formic Acid in water (Solvent A) and 0.1% Formic Acid in acetonitrile (Solvent B) for A Ag using the indicated linear gradient. A mobile phase of 0.1% trifluoroacetic acid in water (Solvent A) and 0.1% trifluoroacetic acid in acetonitrile (Solvent B) was used in all other cases, using the linear gradients specified. After lyophilization, peptides were isolated as TFA, formate or acetate salts depending on the chromatographic eluent.
LC-MS was performed either on a Shimadzu LC-MS 2020 instrument consisting of a LC-M20A pump and a SPD-20A UV/Vis detector coupled to a Shimadzu 2020 mass spectrometer (ESI) operating in positive mode unless otherwise stated, or a Shimadzu UPLC-MS equipped with the same modules as the LC-MS system except for a SPD-M30A diode array detector. Separations were performed on the LC-MS system either on a Waters Sunfire 5 µm, 2.1 x 150 mm column (C-18), or wide-pore equivalent operating at a flow rate of 0.2 mL min -1 . Separations on the UPLC-MS system were performed using a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-8) at a flow rate of 0.6 mL min -1 . Separations were performed using a mobile phase of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) and a linear gradient of 0-50% B over 30 min on the LC-MS System and 0-50% B over 8 min on the UPLC-MS system. Low-resolution mass spectra were recorded on a Shimadzu 2020 mass spectrometer (ESI) operating in positive mode except for A Aa compounds bearing a free sTyr residue which were recorded in negative mode due to the lability of the sulfate groups. Low Resolution MALDI-TOF mass spectra were recorded on a Bruker Autoflex™ Speed MALDI-TOF mass spectrometer operating in linear mode using a matrix of 10 mg/mL sinapinic acid in water/acetonitrile (1:1 v/v) with no TFA.
Cleavage from the Resin
Fully Deprotected Peptide
The resin-bound peptide was treated with an ice-cold TFA, TIS, water, thioanisole mixture (90:5:2.5: 2.5, 5 mL) and allowed to shake at room temperature for 2 hours. At this point, the resin was filtered and washed with fresh cleavage cocktail. The combined cleavage solutions were worked-up as described below.
Side Chain Protected Peptide
The resin was washed with CH 2 Cl 2 (5x 3 mL) before treating with a solution of HFIP/CH 2 Cl 2 (3:7, v/v, 4 mL) and shaken for 40 mins at room temperature. The resin was filtered and washed with CH 2 Cl 2 (3x 3 mL). The combined cleavage solutions and washes were concentrated under nitrogen flow, to afford the crude side chain protected product.
Solution-Phase Thioesterification
A solution of fully side chain protected peptide in dry DMF (20 mM) was treated with the appropriate thiol (30 eq.), iPr 2 NEt (5 eq.) and PyBOP (5 eq.) at -30 °C for 3 hours under an argon atmosphere. The solution was then concentrated under nitrogen flow and subjected to the acidic deprotection conditions described for the fully protected peptide.
Work-up and Purification
Ice-cold diethyl ether (30 mL) was added dropwise to the concentrated cleavage solution to precipitate the crude peptide. The precipitate was then collected via centrifugation and washed with further diethyl ether to remove any remaining scavengers. Residual diethyl ether was removed under gentle nitrogen flow and dissolved in 0.1% TFA aqueous buffer (with minimal addition of MeCN to aid dissolution, if necessary). The crude peptide was analysed by LC-MS (ESI) and purified by RP-HPLC using gradients as indicated.
Insect Cell Expression of A
Aa and A Ag : Synthetic genes encoding anophelin from A. albimanus or A. gambiae fused to the honeybee (Apis mellifera) mellitin secretion signal and with optimized codon usage for expression in insect cells were obtained from commercial suppliers (GenScript (Piscataway, NJ) for A. albimanus or NZYtech (Lisboa, Portugal) for A. gambiae). The synthetic genes were cloned into the BamHI and HindIII restriction sites of the pKL acceptor vector (EMBL, Grenoble, France) 1 and the integrity of the resulting constructs was verified by automatic DNA sequencing. Bacmid preparation, transfection, and protein expression were performed as previously described. Analytical Chromatography: Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 .
Preparative Chromatography: Waters HPLC fitted with a Waters Sunfire C18 column (5 μm, 10 × 250 mm) at a flow rate of 7 mL min −1 using a mobile phase of 0.1% trifluoroacetic acid in water (Solvent A) and 0.1% trifluoroacetic acid in acetonitrile (Solvent B). Analytical Chromatography: Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 .
Preparative Chromatography: Waters HPLC fitted with a Waters Sunfire C18 column (5 μm, 10 × 250 mm) at a flow rate of 7 mL min −1 using a mobile phase of 0.1% trifluoroacetic acid in water (Solvent A) and 0.1% trifluoroacetic acid in acetonitrile (Solvent B).
Nano-liquid chromatography -tandem mass spectrometry of insect cell media: Media were filtered through a 30 kDa molecular weight cut-off membrane and protein quantified by Qubit fluorescence (Thermo Fisher Scientific). The filtrate was aliquoted and either directly loaded onto a C18 solid-phase extraction micro column (3M empore) or digested with trypsin (1:50 trypsin:substrate concentration; 6 h, room temperature) before being loaded onto a C18 micro column. The column was washed with 5% acetonitrile in water and eluted with 60% acetonitrile in water followed by vacuum centrifugation. The purified extract was resuspended in water and analysed on a Dionex 3500RS nanoUHPLC coupled to an Orbitrap Fusion mass spectrometer in positive mode. The mixture was separated using an in-house packed 75 μm x 40 cm pulled column (1.9 μm particle size, C18AQ; Dr Maisch, Germany) with a gradient of 2 -60% acetonitrile containing 0.1% formic acid over 150 min at 300 nl/min. An MS1 scan was acquired from 600 -1800 m/z for intact extracts or 300 -1500 m/z for digested extracts (60,000 resolution; 5e5 AGC, 100 ms injection time) followed by MS/MS data-dependent acquisition with HCD, ETD or EThcD and detection in the orbitrap (60,000 resolution, 2e5 AGC, 120 ms injection time, calibrated charge-dependent ETD reaction times [2+ 121 ms; 3+ 54 ms; 4+ 30 ms; 5+ 20ms; 6+ 13 ms; 7+; 10 ms], 30 NCE for HCD [or 25 NCE for HCD supplemental activation], 1.8 m/z quadrupole isolation width). All data were processed with Proteome Discoverer (v2.1) using SequestHT and manual analysis / annotation using GPMAW (Lighthouse Data, Denmark). The precursor MS and MS/MS tolerance were set to 20 ppm with no enzyme searching. The peptides were searched with the following variable modifications; oxidation of methionine, deamidation of asparagine or glutamine and sulfation of tyrosine.
All RAW and processed data associated with the manuscript has been deposited in PRIDE proteomeXchange (project accession PXD008240), and can be accessed at http://www.proteomexchange.org/ using the username: reviewer16462@ebi.ac.uk and password: YgwNoeaT.
Cell-Free Expression of A
Aa and A
Ag
: Continuous exchange CFPS reactions were carried out as described previously, using either plasmids or PCR amplicons as DNA templates in 10 mL reaction mixtures in a dialysis bag suspended in a 10-fold larger volume of outer buffer. 3, 4 The inner buffer was supplemented with purified aminoacyl-tRNA synthetase (RS) and 0.2 mg/mL total tRNA containing suppressor tRNA CUA . The inner and outer buffers contained the 20 natural amino acids and the unnatural amino acid (each at 1 mM). Except for the additional presence of tRNA CUA , RS and UAA, the reactions were performed at 30 °C overnight as described previously. 3 tRNA CUA , S30 extract and RS were prepared as previously described. 3 A Aa and A Ag were expressed in fusion with N-Terminal His 6 -tagged ubiquitin and purified using a Co-NTA gravity column (GE Healthcare, New York). The elution buffer contained 50 mM Tris-HCl, pH 8.0, 300 mM NaCl and 300 mM imidazole. To cleave off the ubiquitin, His-tagged DUB 5 was added to the purified protein at an enzyme:substrate ratio of 1:100, followed by dialysis against a buffer containing 50 Mm Tris-HCl pH 8.0, 300 mM NaCl and 2 mM β-mercaptoethanol to remove imidazole. Afterwards the sample was loaded onto a Co-NTA gravity column and the flow-through fractions containing A Aa and A Ag were collected. The buffer was exchanged to 50 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM DTT and lyophilized to remove the solvent. The crude protein was then purified via RP-HPLC prior to analysis.
Purification and Characterization of Cfe1
Cfe1 was obtained from CFPS as described above. Purification of the crude peptide by preparative RP-HPLC (0 to 50% B over 40 min, 0.1% FA) afforded peptide Cfe1 as a fluffy white solid after lyophilization (0.3 mg Preparative Chromatography: Semi-preparative reversed-phase HPLC Waters XBridge-BEH300 wide-pore C18 column (5 μm, 10 x 250 mm) at a flow rate of 4 mL min -1 using a mobile phase of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) and a linear gradient of 0-50% B over 40 min.
Low Resolution Mass Spectrometry: Low-resolution mass spectra were recorded on a Shimadzu 2020 mass spectrometer (ESI) operating in positive mode.
In vitro Inhibition of Human α-and γ-Thrombin:
The inhibition of the amidolytic activity of human α-thrombin (Haematologic Technologies, Essex Junction, VT) was followed spectrophotometrically using Tos-Gly-Pro-Arg-p-nitroanilide (Chromozym TH; Roche, Penzberg, Germany) as chromogenic substrate. The inhibition constants (K i ) of all anophelin variants were determined according to a tight-binding inhibitor model, using the Morrison equation. 6 Tight-binding assays were performed using 0.2 nM human α-thrombin, 100 μM substrate, and increasing concentrations (0-80 nM) of inhibitor. The inhibition constant K i was determined by fitting the inhibited steady-state velocity data to the Morrison equation using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). All reactions were carried out at 37 °C in 50 mM Tris·HCl pH 8.0, 50 mM NaCl, 1 mg/mL BSA in 96-well microtiter plates. Reaction progress was monitored at 405 nm for 1-2 h on a Synergy2 Multimode microplate reader (BioTek, Winooski, VT). Dose-response curves (percentage of thrombin activity at 30-45 min as a logarithmic function of the concentration of inhibitor) were used to determine the K i values using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The inhibition of the amidolytic activity of human γ-thrombin (Haematologic Technologies, Essex Junction, VT) was measured as described above for human α-thrombin. The final concentrations of substrate, inhibitor, and γ-thrombin were 100 μM, from 0 to 80 nM or 250 nM (in the case of the non-sulfated A Aa variant), and 0.2 nM, respectively. For each inhibitor, at least two independent experiments with duplicate reactions were performed, together with control reactions in the absence of enzyme. For all curves, the goodness of fitting parameter R 2 was between 0.982 and 0.999.
In vitro Thrombin Inhibitory Activity of Cfe1
Figure S1. Sulfation at Tyr12 improves the human α-thrombin inhibitory activity of A. gambiae anophelin. Dose response curves for the inhibition of α-thrombin activity by increasing concentrations of recombinant variant A Ag cE5 7 (K i = 5.50 ± 1.26 pM) and cell-free system sulfated variant A Ag Cfe1 (1.13 ± 0.21 pM). Inhibition constants (K i ) for both inhibitors were determined by fitting the inhibited steady-state velocity data to the Morrison model. K i values ± SEM given are representative of two independent experiments. Analytical Chromatography: Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 .
Model Thioesterification Studies
To investigate the possibility of epimerization of the C-terminal residue during thioesterification under the optimised protocol at -30 o C, thioesterification of the side-chain protected precursor of 5 (following HFIP cleavage) was repeated under conditions that would promote epimerisation of the Cterminal residue (T30). For this purpose, the reaction was carried out at higher temperature (50 o C) and the order of reagent addition was altered (base, followed by PyBOP, followed by thiol). Following acidolytic side chain deprotection UPLC-MS (0 to 60% B over 5 min, 0.1% FA) analysis was performed on the crude products generated from the optimised thioesterification protocol (at -30 o C) and those from the alternative thioesterification conditions (50 o C). Performing the reaction under epimerisation-prone conditions (50 o C) resulted in significant epimerization (ca. 2:3 epi-5 (green):5 (blue) see Figure S2A ). Both epimers were shown to possess an identical mass ([M+2H] 2+ =1703.3). In contrast, performing the thioesterification reaction under optimised conditions (-30 o C) led to a single diastereomer that matched the retention time of the major epimer in Figure S2A (see Figure S2B for crude reaction and Figure S2C for coinjection). Purification via reverse phase HPLC as described in the experimental above then provided peptide thioester 5 as a single epimer ( Figure  S2D ). HCl, 100 mM Na 2 HPO 4 , 10 mM TCEP, adjusted to pH 7.5) was added to the appropriate peptide thioester (1.1 eq.). The resulting solution was carefully readjusted to pH 7.2 with 1 M KOH, TFET (2 vol. %) added and the reaction incubated at 30°C. After complete conversion to the desired ligation product (judged by UPLC-MS analysis), a neutral solution of TCEP (400 mM) and reduced glutathione (80 mM) in buffer (6 M Gn . HCl, 100 mM Na 2 HPO 4 ) was then added to give a final 200 mM concentration of TCEP, a 40 mM concentration of reduced glutathione, and a 2.5 mM final concentration of the peptide. The resulting solution was adjusted to pH 6.5 and then degassed by sparging with argon for 10 min which also removed the excess TFET from the reaction mixture. VA-044 (to give a concentration of 20 mM) was then added in solid form and the reaction mixture was further sparged with argon to aid VA-044 dissolution. The reaction was then incubated at 37 °C. After UPLC-MS analysis showed complete conversion to the desulfurized product the reaction mixture was diluted and immediately purified by RP-HPLC.
Analytical Chromatography: Waters system 2695 separations module fitted with an X-Bridge BEH 1.7 µm 2.1 x 50 mm wide-pore column (C-18) at a flow rate of 0.2 mL min -1 .
Semi-Preparative Chromatography:
Waters HPLC fitted with a Waters X-Bridge-BEH300 (C-18) column (5 μm, 10 × 250 mm) at a flow rate of 4 mL min −1 using a mobile phase of 0.1 M NH 4 OAc in water (Solvent A) and acetonitrile (Solvent B) and a linear gradient of 0-30% B over 60 min. Figure S3 . Synthesis of Syn2: Syn2 was assembled from 6 and 7 as described in the general procedures. Crude reaction traces were obtained using a Waters System 2695 separations module fitted with an XBridge BEH 5 µm, 2.1 x 150 mm wide-pore column (C-18) (0 to 60% B over 30 min, 0.1% TFA, λ= 214 nm) at a flow rate of 0.2 mL min -1 . Analytical traces were obtained using a Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) (0 to 100% B over 5 min, 0.1% TFA, λ= 214 nm) at a flow rate of 0.6 mL min -1 . Low-resolution mass spectra of crude reactions and purified Syn2 were recorded on a Shimadzu 2020 mass spectrometer (ESI) operating in positive or negative mode. Syn2 was purified via semi-preparative reversed-phase HPLC Waters XBridge-BEH300 wide-pore C18 column (5 μm, 10 x 250 mm) at a flow rate of 4 mL min -1 using a mobile phase of 0.1 M NH 4 OAc (Solvent A) and acetonitrile (Solvent B) and a linear gradient of 0-30% B over 60 min. Figure S4 . Synthesis of Syn3: Syn3 was assembled from 5 and 8 as described in the general procedures. Crude reaction traces were obtained using a Waters System 2695 separations module fitted with an XBridge BEH 5 µm, 2.1 x 150 mm wide-pore column (C-18) (0 to 60% B over 30 min, 0.1% TFA, λ= 214 nm) at a flow rate of 0.2 mL min -1 . Analytical traces were obtained using a Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) (0 to 100% B over 5 min, 0.1% TFA, λ= 214 nm) at a flow rate of 0.6 mL min -1 . Low-resolution mass spectra of crude reactions and purified Syn3 were recorded on a Shimadzu 2020 mass spectrometer (ESI) operating in positive or negative mode. Syn3 was purified via semi-preparative reversed-phase HPLC Waters XBridge-BEH300 wide-pore C18 column (5 μm, 10 x 250 mm) at a flow rate of 4 mL min -1 using a mobile phase of 0.1 M NH 4 OAc (Solvent A) and acetonitrile (Solvent B) and a linear gradient of 0-30% B over 60 min. Figure S5 . Synthesis of Syn4: Syn4 was assembled from 6 and 8 as described in the general procedures. Crude reaction traces were obtained using a Waters System 2695 separations module fitted with an XBridge BEH 5 µm, 2.1 x 150 mm wide-pore column (C-18) (0 to 60% B over 30 min, 0.1% TFA, λ= 214 nm) at a flow rate of 0.2 mL min -1 . Analytical traces were obtained using a Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) (0 to 100% B over 5 min, 0.1% TFA, λ= 214 nm) at a flow rate of 0.6 mL min -1 . Low-resolution mass spectra of crude reactions and purified Syn4 were recorded on a Shimadzu 2020 mass spectrometer (ESI) operating in positive or negative mode. Syn4 was purified via semi-preparative reversed-phase HPLC Waters XBridge-BEH300 wide-pore C18 column (5 μm, 10 x 250 mm) at a flow rate of 4 mL min -1 using a mobile phase of 0.1 M NH 4 OAc (Solvent A) and acetonitrile (Solvent B) and a linear gradient of 0-30% B over 60 min.
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Synthesis of A Ag Peptide Fragments
Peptide thioester 12 was prepared according to Fmoc-strategy SPPS, through a combination of automated and manual synthesis, on 2-chlorotrityl chloride resin (50 µmol), followed by solution- 3+ .
Absorbance (AU)
Analytical Chromatography: Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 .
Peptide thioester 13 was prepared according to Fmoc-strategy SPPS, through a combination of automated and manual synthesis, on 2-chlorotrityl chloride resin (25 µmol), followed by solutionphase thioesterification with ethyl-3-mercaptoproprionate (95 µL, 30 eq.) as outlined in the general procedures. Removal of all the acid labile protecting groups was achieved via treatment of the crude peptide thioester with a solution of TFA/TIS/H 2 O/thioanisole (90:5:2.5:2.5 v/v/v/v, 4 mL) for 2 hours at room temperature. The deprotection solution was then concentrated under nitrogen flow and the crude thioester precipitated from ice-cold diethyl ether. Purification of the crude peptide by preparative RP-HPLC (18 to 28% B over 35 min, 0.1% TFA) afforded peptide 13 as a fluffy white solid after lyophilization (14. Analytical Chromatography: Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 .
General Protocol for One Pot Ligation-Desulfurization of A
Ag
A 5 mM solution of peptide 13 (1.0 eq.) in ligation buffer (6 M Gn . HCl, 100 mM Na 2 HPO 4 , 20 mM TCEP, adjusted to pH 6.3) was added to peptide TFET-thioester 12 (1.1 eq.). The resulting solution was carefully readjusted to pH 6.2 with 1 M KOH and the reaction incubated at 25 °C. Upon quantitative conversion to the corresponding ligated peptide 15 (UPLC-MS monitoring), peptide 14 (1.2 eq.) was added, followed by TFET (2 vol. %). The pH of the resulting solution was subsequently adjusted to pH 7.1 and the reaction was incubated at 25 °C for 16 hours. After complete conversion to the ligation product 16 (UPLC-MS analysis), a neutral solution of TCEP (400 mM) and reduced glutathione (100 mM) in buffer (6 M Gn . HCl, 100 mM Na 2 HPO 4 ) was then added to give a final 200 mM concentration of TCEP, a 50 mM concentration of reduced glutathione, and a 2.5 mM final concentration of the peptide. The resulting solution was adjusted to pH 6.2 and then degassed by sparging with argon for 10 min which also removed the excess TFET from the reaction mixture. VA-044 (to give a concentration of 5 mM) was then added in solid form and the reaction mixture was further sparged with argon to aid VA-044 dissolution. The reaction was then incubated at 37 °C. After UPLC-MS analysis showed completed conversion to the desulfurized product the reaction mixture was diluted and immediately purified by RP-HPLC. Analytical Chromatography: Waters Acquity UPLC system fitted with a Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 .
Synthesis of A
Semi-Preparative Chromatography:
Waters HPLC fitted with a Waters X-Bridge-BEH300 C18 column (5 μm, 10 × 250 mm) at a flow rate of 4 mL min −1 using a mobile phase of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B). Figure S6 . Synthesis of Syn1: Syn1 was assembled from 12. 13 and 14 as described in the general procedures. Crude and analytical reaction traces were obtained using a Waters Acquity UPLC system fitted with an Waters Acquity UPLC BEH 1.7 µm 2.1 x 50 mm column (C-18) at a flow rate of 0.6 mL min -1 (0 to 50% B over 5 min, 0.1% TFA, λ= 214 nm). Low-resolution mass spectra of crude reactions and purified Syn1 were recorded on a Shimadzu 2020 mass spectrometer (ESI) operating in positive or negative mode. Syn1 was purified via semi-preparative reversed-phase HPLC on a Waters XBridge-BEH300 wide-pore C18 column (5 μm, 10 x 250 mm) at a flow rate of 4 mL min -1 using a mobile phase of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) and a linear gradient of 0-50% B over 40 min.
Tail Bleeding and Activated partial thromboplastin time (aPTT) Experiments:
Animals: Male C57Bl/6 mice weighed at 21-25 grams and 18-20 grams were used for tail bleeding assay and needle injury model, respectively. C57Bl/6 mice were all sourced from Australian BioResources (ABR, Moss Vale, NSW Australia). All procedures involving the use of mice were approved by the University of Sydney Animal Ethics Committee (Project # 620). All animals were housed in specific pathogen free (SPF) facility in accordance with the Australian code of practice for the care and use of animals for scientific purposes and maintained on a 12/12 h light/dark cycle and allowed free access to food and water. Animals were fully anaesthetized with a mixture of ketamine (150 mg/kg) and xylazine (15 mg/kg) and body weight was measured before all experimental procedures.
Study design:
To test the potency of each of the thrombin inhibitors each compound was added to pooled normal plasma at concentrations of 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.4, 1.6, 2, 4 
Tail bleeding assay:
Anaesthetized animals were placed on a 37 °C heating blanket with supplement of oxygen. Based on measured weights, animals were administered intravenously with DTI candidates at different doses. Within 5 min, animals were placed in prone position and a distal 3-mm segment of the tail was amputated with a scalpel. The cut tail was immediately immersed in pre-warmed saline contained in a 50-mL Falcon tube. Bleeding for each animal was monitored for a total of 20 min from the time of tail immersion. On/off cycles of bleeding were recorded and the sum of bleeding times within the 20 min period were added up as total bleeding time (min). After 20 min of bleeding (25 min post drug administration), blood was immediately collected into syringe containing 129 mM sodium citrate for aPTT assay.
Activated partial thromboplastin time (aPTT) assay: Citrated blood was centrifuged at 4 °C, 13,400 rpm for 15 min to obtain plasma. aPTT was measured by using an aPTT kit according to the manufacturer's instructions (Randox Laboratories, UK). All reagents (R1 & R2) and fresh plasma were pre-warmed before aPTT measurement. 0.1 mL aPTT R1 (purified soy bean phosphatides and Ellagic acid) was mixed well with 0.1 mL plasma in a transparent glass tube and incubated for 3 min at 37 °C. Next, 0.1 mL aPTT R2 (Calcium Chloride) was added to the mixture to initiate the reaction. The time taken for the mixture turning from transparent to opaque/white web-like precipitate as an indication of fibrin formation was recorded after addition of aPTT R2. The dose response effects of the DTI candidates on tail-bleeding time and aPTT were plotted and compared. 
